A Phase 1/2, First in Human, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Triple-Specific T-Cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-Cell Hematologic Malignancies

Protocol No
CHIMAGEN-CMG1A46-US01
Phase
I/II
Summary

The purpose of this study is to find out about the safety and efficacy of an experimental drug
called 1A46 for the treatment of B-cell non-Hodgkin lymphoma (NHL) and B-cell acute
lymphoblastic leukemia (ALL). Experimental means that 1A46 is not approved by the U.S. Foodand Drug Administration (FDA). This study will be the first time 1A46 is given to humans.

Description
A Phase 1/2 Study to Evaluate CMG1A46 in Patients with CD20 and/or CD19 Positive B-cell Hematologic Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL